Full Press Release Details
ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP)
Immutep to Present at Ladenburg Thalmann 2018 Healthcare Conference
SYDNEY, AUSTRALIA September 26, 2018 Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep or
the Company ), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, announced today that it has been invited to present at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, Oct.
2, 2018, at the Sofitel Hotel in New York City.
Marc Voigt, CEO of Immutep, is scheduled to present a corporate overview and business update at 3:30pm ET
on Tuesday, October 2, 2018, with one-on-one meetings held throughout the day. The presentation will be webcast live via the following webcast link and a
replay will be available via the investors & media section of the Company s website.
Immutep is a globally active biotechnology company that is a leader in the development of immunotherapeutic products for the treatment of cancer and autoimmune
disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders.
Immutep s current lead product is eftilagimod alpha ( efti or IMP321 ), a soluble LAG-3Ig
fusion protein based on the LAG-3 immune control mechanism. This mechanism plays a vital role in the regulation of the T cell immune response. Efti is currently in a Phase IIb clinical trial as a
chemoimmunotherapy for metastatic breast cancer termed AIPAC (clinicaltrials.gov identifier NCT 02614833); a Phase II clinical trial referred to as TACTI-002 (Two ACTive Immunotherapies) to evaluate a
combination of Efti with KEYTRUDA (pembrolizumab) in several different solid tumours (clinicaltrials.gov identifier NCT03625323); and a Phase I combination therapy trial in metastatic
melanoma termed TACTI-mel (clinicaltrials.gov identifier NCT 02676869). Additional LAG-3 products, including antibodies, for immune response modulation in autoimmunity and cancer are being developed by
Immutep s large pharmaceutical partners. Immutep is also developing an agonist of LAG-3 (IMP761) for autoimmune disease.
Immutep is listed on the Australian Securities Exchange (IMM), and on the NASDAQ (IMMP) in the United States.
Further information can be found on the Company s website www.immutep.com or by contacting:
Jay Campbell, Vice President of Business
Development and Investor Relations, Immutep Limited
+1 (917) 860-9404; jay.campbell@immutep.com
Garth Russell, LifeSci Advisors
+1 (646) 876-3613; garth@lifesciadvisors.com
Australian Investors/Media:
Matthew Gregorowski, Citadel-MAGNUS